Natco Pharma announced its unaudited consolidated financial results for the quarter ended December 31, 2025, demonstrating steady performance with revenue growth and sustained profitability. The pharmaceutical company reported consolidated total revenue of ₹705.4 crore for Q3FY26, marking an increase from ₹651.1 crore recorded in the corresponding quarter of the previous year.

Financial Performance Highlights

The company's financial metrics for Q3FY26 showed robust operational performance across key parameters:

For the nine months ended December 31, 2025, the company reported total income of ₹35,590 million compared to ₹34,967 million in the corresponding period last year. Net profit for the nine-month period stood at ₹11,495 million against ₹14,774 million in the previous year.

Segment-wise Revenue Performance

The company's business segments showed varied performance during Q3FY26:

The pharmaceuticals segment contributed ₹6,189 million to revenue, while agro chemicals generated ₹284 million during the quarter.

Board Decisions and Corporate Actions

The Board of Directors approved several significant decisions during their meeting held on February 12, 2026:

Dividend Declaration:

• Third interim dividend of ₹1.50 per equity share (75%) for FY2025-26
• Record date: February 18, 2026
• Payment date: February 26, 2026

Key Appointments:

• Mr. Amit Parekh appointed as Chief Financial Officer effective February 13, 2026
• Mr. Kalakuntla Srinivas Rao appointed as Executive Vice President – Pharma Division
• Superannuation of Mr. S. V. V. N. Appa Rao as CFO effective February 12, 2026

Strategic Developments

The company announced plans to incorporate a wholly owned subsidiary in Chile named NATCO Pharma Chile SPA with an investment of up to US$ 3,00,000. Additionally, the Board approved the re-constitution of the Environmental, Social and Governance Committee and Risk Management Committee effective February 13, 2026.

Associate Company Performance

Natco Pharma's associate company, Adcock Ingram Holdings Limited in South Africa, contributed ₹109 million as share of profit during the quarter. The acquisition of 35.75% stake in Adcock Ingram was completed on November 11, 2025, for a total consideration of ZAR 3,873 million (USD 225 million).

Re-appointments and Governance

The Board recommended re-appointment of key directors for one-year terms effective April 1, 2026:

• Sri Venkaiah Chowdary Nannapaneni as Chairman & Managing Director
• Sri Rajeev Nannapaneni as Vice Chairman & Chief Executive Officer
• Sri Potluri Sivaramakrishna Prasad as Director and Executive Vice President
• Dr. Donthineni Linga Rao as Director & President (Technical Affairs)

These re-appointments are subject to shareholder approval through postal ballot.

Natco Pharma Limited has announced its third interim dividend for the financial year 2025-26, demonstrating the company's commitment to returning value to shareholders. The pharmaceutical company's Board of Directors approved the dividend declaration during their meeting held on February 12, 2026.

Dividend Declaration Details

The company has declared an interim dividend with specific parameters that shareholders should note:

This marks the third interim dividend payment by the company for the current financial year, indicating consistent cash flow generation and management's confidence in the business performance.

Eligibility and Payment Timeline

Shareholders who are on the company's records as of the close of business on February 18, 2026, will be eligible to receive the interim dividend payment. The company has established a clear timeline for the dividend process, with payments scheduled to begin on February 26, 2026.

The dividend amount of Rs 1.50 represents 75% of the face value of each equity share, which is valued at Rs 2.00. This calculation demonstrates the substantial return being provided to shareholders through this interim distribution.

Regulatory Compliance

The dividend declaration has been made in accordance with Regulation 42 of the Securities and Exchange Board of India (SEBI) regulations. The company has duly informed both major stock exchanges where its shares are listed - BSE Limited (Scrip Code: 524816) and National Stock Exchange of India Limited (Scrip Code: NATCOPHARM).

The announcement was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, ensuring proper corporate governance procedures were followed in the dividend declaration process.